Fierce Pharma has another one of the type of articles we've been seeing a lot of — one that looks at...

Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Fierce Pharma has another one of the type of articles we've been seeing a lot of — one that looks at...
Pharmaceutical Technology wonders, "Why can’t the US figure out weight loss drug prices?" and APC CE...
Patients in the Dallas area are feeling the sticker shock of the end of the GLP-1 shortages. APC's S...
APC, along with several other organizations, has been fighting hard to protect California firefighte...
Over the last few weeks, with the FDA declaring the end of the GLP-1 shortages, APC’s reporter hotli...
In "Zepbound copycats remain online despite FDA ban," it looks at ways some compounders are continui...
How will the new administration regulate weight-loss drugs? The truth is, we don't know yet. Forbes ...
We’re pretty happy with Newsday’s coverage of how patients taking GLP-1 drugs will be affected by th...
The Wall Street Journal is looking past the FDA’s official ending of the GLP-1 shortages and into th...
The Royal Society of Chemistry's Chemistry World has a terrific piece on the ending of the semagluti...
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.